The cytokine interleukin-16 is generated by posttranscriptional cleavage by caspase-3 of two large precursor isoforms. The smaller protein of 67 kDa (pro-IL-16) is expressed in cells of the immune system and contains three PDZ (postsynaptic density/disc large/zona occludens-1) domains, whereas the larger 141-kDa neuronal variant (npro-IL-16) has two additional PDZ domains in its N-terminal extension that interact with neuronal ion channels. Using the yeast two-hybrid approach we have identified three closely related myosin phosphatase targeting subunits, MYPT1, MYPT2, and MBS85, as binding partners of the IL-16 precursor proteins. These interactions were verified using pull-down assays, coimmunoprecipitations, and plasmon resonance experiments. 
Interleukin-16 (IL-16)
1 is a cytokine with diverse immunomodulatory functions and is implicated in several inflammatory processes and disorders including asthma, rheumatoid arthritis, Crohn's disease, and multiple sclerosis (1) (2) (3) (4) (5) . It is a potent chemoattractant factor for CD4
ϩ T-cells and regulates proliferation and activation of lymphocytes and the release of pro-inflammatory cytokines (2, 6) . IL-16 functions also as an inhibitor of human and simian immunodeficiency virus replication and induces signaling via binding to the CD4 cell surface receptor (7, 8) . The cytokine is synthesized as a large precursor protein and is released as a C-terminal 121-amino acid fragment after cleavage by caspase-3, reminiscent of the processing of pro-IL-1 by caspase-1 (9, 10). Two major forms of the IL-16 precursor are known. A 67-kDa protein (pro-IL-16) is almost exclusively expressed in leukocytes and lymphatic tissues, whereas the much larger 141-kDa neural precursor (npro-IL-16) seems to be confined to special neurons including CD4 ϩ granule cells of the cerebellum and hippocampus (11) . To date only the sequence of mouse npro-IL-16 has been published (11) . This protein represents an N-terminal extension of pro-IL-16 for which transcription is most likely induced by an alternative neural promoter, representing an unexpected connection between the immune system and the nervous system.
Pro-IL-16 exhibits significant interspecies homology and contains three highly conserved PDZ domains (12, 13) . The npro-IL-16 comprises two further PDZ domains in addition to other putative interaction modules. PDZ domains are characteristic sequences of 80 -90 amino acids that share a common fold (14) . A typical interaction involves the association of the carboxyl end of the ligand with the peptide binding groove of the PDZ domain (15) . It has been shown, however, that PDZ domains can also participate in other modes of protein interaction (16) . Proteins containing PDZ domains play crucial roles in the assembly of miscellaneous macromolecular signaling complexes and in the targeting of their components to specialized subcellular locations including synapses and other membrane microdomains (17) . A predominantly indirect association with the cytoskeleton and cellular motor proteins is critical for the function of many of these proteins.
Using a yeast two-hybrid approach, Kurschner and Yuzaki (11) show subunits of NMDA receptors, inward rectifier, and voltage-gated potassium channels as well as the ␣1 subunit of the voltage-sensitive class C calcium channel to be binding partners of the two PDZ domains encoded exclusively in npro-IL-16. However, proteins interacting with the three C-terminal PDZ domains shared by both IL-16 precursor forms remain elusive (11) . Recently it has been demonstrated that the HTLV type 1 tax protein interacts with the PDZ1 region of pro-IL-16 (18) .
The presence of protein interaction domains in the IL-16 precursors strongly suggests that in addition to their function as a source of the cytokine, these proteins are involved in other cellular processes possibly related to the cleavage, transport, or release of the mature cytokine. Alternatively they may play a * The work was supported by a Deutscher Akademischer Austauschdienst fellowship (to B. A.) and by a grant from the Heinz Kuthe-de Mouson Foundation (Bole, Switzerland) (to R. K.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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EXPERIMENTAL PROCEDURES
Yeast Two-hybrid Assays-Two-hybrid experiments were performed using the DupLEX-A system (OriGene Technologies, Rockville, MD). Two commercially available cDNA libraries, an oligo(dT)-primed PBL library cloned into the pJG4 -5 vector (OriGene) and a random-primed spleen library in the pYESTrp2 vector (Invitrogen) were utilized. The library plasmids were introduced into the EGY48 yeast strain previously transformed with the lacZ-reporter plasmid pSH18 -34 (OriGen) and the pEG202/PDZ1-3 bait construct. The transformants were plated on yeast nitrogen base-(Gal) quadruple-minus plates (LeuϪ, TrpϪ, UraϪ, and HisϪ) containing 5-bromo-4-chloro-3-indolyl-␤-D-galactopyranoside (X-gal) to detect potential positive blue colonies after 3-4 days at 30°C. Plasmid DNA was isolated from these clones and transformed into the KC8 bacterial strain to recover the library plasmid. To confirm the screening results, recovered plasmids were reintroduced in combination with relevant and irrelevant control bait vectors into pSH18-34-containing EGY48 yeast. At least three colonies of each transformation were plated on glucose-or galactose-containing selective media, as recommended by the manufacturer. The library plasmid inserts with a confirmed interaction (blue yeast colonies) were sequenced. A similar two-hybrid test with mutants and subsequences of the pro-IL-16 bait and MYPT1, MYPT2, or MBS85 targets was used to identify the interacting protein regions.
Plasmid Constructs and Primers for RT-PCR-The pEG202/PDZ1-3 bait plasmid was constructed by amplifying the PDZ1-3-containing pro-IL-16 sequence (aa 324 -631) with the primer pair 5PDZ1 (5Ј-CA-GGCTGGATCCCCATGACATCATCATCCAACGAAGAC) and 3PDZ3 (5Ј-GACATCGAATGCGGCCGCTAGGAGTCTCCAGCAGCTGT) and fusing it in-frame to the LEX-A protein of pEG202 (OriGene) utilizing the BamHI/NotI cloning sites. To localize the interacting region, subsequences of pEG202/PDZ1-3 consisting of the PDZ2-3 (aa 391-631), PDZ3 (aa 502-631), PDZ2 (aa 391-501, 405-501, and 405-473) and the two N-terminal PDZ domains of the npro-IL-16, nPDZ1-2 (aa 183-457), were amplified by PCR using primer pairs containing EcoRI/NotI restriction sites and cloned in-frame into pEG202. The mutation of the PDZ2 GLGF sequence to KSGS was introduced using the QuikChange site-directed mutagenesis kit (Stratagene), the oligonucleotide 5Ј-CAC-AAGGAGGAAGGTGCTAAGTCTGGGTCAAGCTTGGCAGGAGGAG-CA, and a reverse complement version. The construct pYESTrp2/ MYPT2-(953-982) was cloned by amplifying the C-terminal 30 aa and the subsequent 3Ј-untranslated region present in the retrieved library plasmid pYESTrp2/MYPT2-(855-982) using the sense primer 5Ј-ACT-GAATTCTGATGAAGGTGTTAACAGAACTGAAAT and the pYesTrp reverse primer as the antisense primer. The amplified fragment was cloned in-frame with the activation domain into the empty pYESTrp2 vector (Invitrogen) using the EcoRI/NotI/restriction sites. The construct pYESTrp2/MYPT2-(962-982) was cloned in a similar way using the primer 5Ј-ACTGAATTCTGGACAACCAGAGGCTGAAAGATG as the sense primer. C-terminal MYPT2 target mutants for the yeast twohybrid tests were created by PCR using pYESTrp2/MYPT2-(855-982) as template and the pYesTrp forward primer (OriGene) with the indicated antisense primer introducing the deletion or mutation: MYPT2-(855-978), 5Ј-ACTAATGTAAGCGGCCGCCTAGCTGATGACTCTGAT-GAGGGCACC; MYPT2-(855-980), 5Ј-ATAATGTAAGCGGCCGCCTA-CAGTTTGCTGATGACTCTGATGAG; MYPT2-(855-981), 5Ј-ATAATG-TAAGCGGCCGCCTAGGACAGTTTGCTGATGACTCTGAT; MYPT2-(855-982ϩA), 5Ј-ATAATGTAAGCGGCCGCCTAAGCCTTGGACAGTT-TGCTGATGACTCT; MYPT2-(855-982, K982A), 5Ј-ATAATGTAAG-CGGCCGCCTAAGCGGACAGTTTGCTGATGACTCTGA; MYPT2-(855-982, S981A), 5Ј-ATAATGTAAGCGGCCGCCTACTTAGCCA-GTTTGCTGATGACTCTGAT; MYPT2-(855-982, L980A), 5Ј-ATAATG-TAAGCGGCCGCCTACTTGGAAGCTTTGCTGATGACTCTGAT. The amplified fragments were cloned into pYESTrp2 using the EcoRI/NotI restriction sites. For the production of His 10 -tagged PDZ2 (aa 391-501) and PDZ3 (aa 502-631), the respective cDNA sequence was PCRamplified and cloned in-frame into the pET16b vector (Novagen) using the NdeI/BamHI restriction sites. GST fusion proteins of MYPT2 were created by amplifying aa 855-982 and a C-terminal 4-aa deletion mutant (aa 855-978) of MYPT2. The amplified fragments were cloned in-frame into the pGEX-5X-1 vector (Amersham Biosciences) using the EcoRI/NotI sites. The pcDNA3/pro-IL-16-V5 construct was generated by fusing the DNA sequence coding for the V5 tag in-frame to the 3Ј end of the pro-IL-16 cDNA. This was achieved by PCR using an antisense primer coding for the V5 tag and inserting the amplified pro-IL-16-V5 fragment into pcDNA3 (Invitrogen). Vectors encoding the cDNA sequence of MYPT2 and MYPT1 were a generous gift of Dr. Masaaki Ito (Mie University, Japan). The entire coding sequences of MYPT2 and MYPT1 were amplified and cloned into the pCMV-Tag3B vector (Stratagene) using the EcoRI/NotI restriction sites. The resulting pCMV/ MYPT2 and pCMV/MYPT1 vectors allow the expression of the fulllength proteins containing the Myc tag on the N terminus. The pCMV/ MYPT2-(657-982), pCMV/MYPT2-(657-978), and pYesTrp2/MYPT1-(904 -1030) constructs were made by PCR amplification of the indicated subsequence of MYPT2 or MYPT1 and insertion into pCMV3-Tag3B and pYesTrp2, respectively. The pXJ-FLAG-MBS85 plasmid for the expression of FLAG-MBS85 was contributed by Thomas Leung (Glaxo-IMCB Group, Singapore) and has been described previously (19) .
For RT-PCR amplification of MYPT2 transcripts the primers Ex 20 (forw), 5Ј-ACCAGCCGTGTAGAAGAAGACAGCAAC; Ex 25 (rev), 5Ј-T-CTTTCCTCATAAATCTGGAGCCTAGCC; Ex 13 (forw), 5Ј-AGCTACT-CCTGTGCTCTCCATTACTGG, and In 13 (forw), 5Ј-CTGAGTTGAGA-CATCAGCAAGTGCTGG, were used. MYPT1 transcripts were amplified using the oligonucleotide 5Ј-AACCAGTTCTACATCAGCTG-GTGATCG as forward primer and 5Ј-ACTGCCAATTATGGTCCACTG-GGTTAC as reverse primer. For MBS85 amplification, 5Ј-GGAGGCT-TTAGGACGCTGTATGCAGAG and 5Ј-GTGGCAGAAGCAGCTGTAT-AAATACGG were used as forward and reverse primers, respectively.
Recombinant Proteins-His 10 -tagged PDZ2 and PDZ3 domains were produced in Escherichia coli strain BL21(DE3) as described previously (7) . Briefly, cultures in late logarithmic growth phase were induced with 1 mM isopropyl-␤-D-thiogalactopyranoside for 3 h. Bacterial pellets were frozen, thawed, and resuspended in 50 ml of PBS containing 1% Nonidet P-40, 1 mg of lysozyme, 5-10 units of benzonase, and protease inhibitor mixture (Roche Applied Science). The suspension was sonicated and incubated on ice for 20 -30 min. Recombinant proteins were extracted from cleared lysates by nickel nitrilotriacetic acid-agarose (Qiagen) followed by washes with PBS containing 10 mM imidazole. The fusion protein was eluted with 250 mM imidazole and dialyzed against PBS.
Recombinant GST fusion proteins were produced in E. coli strain BL21. The pellet of induced cells was resuspended in 50 ml of PBS containing 1% Triton X-100, 1 mg of lysozyme, 5-10 units of benzonase, and protease inhibitor mixture (Roche Applied Science). After sonication, the preparation was incubated on ice for 30 min and cleared by centrifugation. Glutathione-Sepharose 4B (Amersham Biosciences) was added to adsorb the soluble GST fusion proteins. After extensive washing with PBS, the suspension was transferred to a column, and the recombinant protein was eluted with 10 mM reduced glutathione in 50 mM Tris-HCl, pH 8, buffer followed by a dialysis in PBS.
In Vitro Binding Assays-3 g of GST fusion proteins and 3 g of the His 10 -PDZ domain containing purified recombinant proteins were diluted in 500 l of GST binding buffer consisting of 1% Triton X-100, 100 mM NaCl, 10 mM MgCl 2 , 0.1% bovine serum albumin, and protease inhibitor mix (Roche Applied Science). Glutathione-Sepharose 4B was added, and after a 2-h incubation at 4°C on a rotator, the beads were extensively washed with binding buffer containing 0.02% SDS and no bovine serum albumin. After the final wash, the beads were resuspended in sample buffer, and bound proteins were analyzed by standard gel electrophoresis followed by Western blotting using INDIA HisProbe-HRP (Pierce) and the ECL Western blotting detection reagents (Amersham Biosciences).
Surface plasmon resonance measurements were performed using a BIAcore 1000 system (BIAcore AB, Uppsala, Sweden). Similar amounts of GST fusion proteins of MYPT2-(855-982) and MYPT2-(855-978) were immobilized on CM5 sensor chips using an amine coupling kit. Association and dissociation reactions with several concentrations of His 10 -PDZ2 in running buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.005% Surfactant P20) were detected as changes of the surface plasmon resonance signal expressed as resonance units.
Immunoprecipitation and Immunoblotting-HEK 293T cells were transfected in 10-cm dishes using Superfect Reagent (Qiagen). For immunoprecipitation, transfected cells and primary PBLs were treated with 1 ml of lysis buffer (1% Triton X-100, 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, and protease inhibitor mix) for 20 min at 4°C followed by centrifugation to remove cell debris. 0.5 g of antibody and 20 l of a 50% protein A-Sepharose (Amersham Biosciences) suspension were added to the cleared lysates. For precipitation of proteins carrying V5, Myc, and FLAG tags, antibodies covalently linked to Sepharose were used. After a 4-h incubation at 4°C on a rotator, the precipitates were washed 5 times with lysis buffer supplemented with 0.02% SDS to reduce unspecific binding. The precipitates were separated on SDSpolyacrylamide gels, transferred to polyvinylidene difluoride membranes (Bio-Rad), and detected by standard Western blotting using enhanced chemiluminescence (ECL, Amersham Biosciences).
Cell Culture-HEK 293T cells were grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum supplemented with 100 units/ml penicillin, 100 g/ml streptomycin, and 2 mM glutamine. COS-7 cells were cultured in CMRL (Connaught Medical Research Laboratories) medium containing the same supplements. PBLs were isolated on a Ficoll-Paque gradient and cultured for 3-4 days in RPMI 1640 medium containing 10% fetal bovine serum, 100 units/ml penicillin, 100 g/ml streptomycin, 2 mM glutamine, 2 g/ml phytohemagglutinin (Sigma), and 180 IU of interleukin-2 (Roche Applied Science).
Antibodies-Anti-IL-16 clone 14.1, the IgG 2A control, and the MYPT1-specific monoclonal antibody were purchased from BD Pharmingen. Goat polyclonal anti-IL-16 was obtained from R&D Systems. Monoclonal anti-V5 tag and anti-FLAG tag (M2) antibodies coupled to agarose beads, anti-FLAG (M2)-HRP, anti-mouse IgG-HRP used as secondary antibody in immunoblots, polyclonal rabbit anti-Myc, and rabbit anti-FLAG as well as the rabbit anti-myosin (smooth and skeletal muscle) serum used in confocal microscopy experiments were all purchased from Sigma. The monoclonal anti-V5 and anti-V5-HRP was obtained from Invitrogen. Anti-Myc (9E10) and control IgGs, free and immobilized on agarose, as well as the anti-Myc-HRP antibody were purchased from Santa Cruz Biotechnology. The goat anti-mouse IgGCy3 and goat anti-rabbit IgG-FITC were obtained from Dianova.
Immunofluorescence Microscopy-Cells were grown in 6-well plates, transfected using Superfect Reagent (Qiagen), and transferred the next day into Lab-Tek chamber slides (Nalge Nunc). 24 h later, cells were fixed with 2% formaldehyde (Sigma) in PBS for 30 min, rinsed briefly in PBS, permeabilized with 0.5% Triton X-100 in PBS for 15 min, and washed 3 times with PBS. After a 20 min incubation with blocking buffer (PBS with 1% Marvel nonfat milk) cells were incubated with the primary antibodies diluted in blocking buffer for 60 min at 37°C. F-actin was stained with FITC-phalloidin (Sigma). The slides were extensively washed with PBS, and the secondary antibodies conjugated to fluorophores were added for 30 min. After thorough washing steps with PBS, the cells were mounted in Mowiol. Images were obtained on a Zeiss (LSM510, Axioplan 2) confocal laser scanning microscope.
Cloning of the Human Neural Pro-IL-16 cDNA-
The human cerebellum Marathon-Ready cDNA (Clontech) and the pro-IL-16-specific antisense primer 5Ј-CAGTGGCAGCAGCTCTCTCGCTTCCTG were used to amplify the new cDNA sequence coding for the N-terminal region of human neural pro-IL-16. The sequence of the antisense primer corresponds to a segment of the 5Ј-untranslated region of pro-IL-16 expressed in lymphatic tissues (10) . Based on the amplified sequence, which exhibited high homology to the known mouse cDNA of neural pro-IL-16 (11), we identified the corresponding start codon of the human sequence. To generate a full-length cDNA sequence of the human neural pro-IL-16, the Marathon-Ready cDNA was used as template in a PCR with the sense primer 5Ј-ACAACAGGTACCGCCGCCATGGAGT-CACACAGCCGCGCTGGA (KpnI site underlined) and antisense primer 5Ј-ATCAGGGAGCCCTCTTGGGTCTGAAGC to amplify the region of aa 1-811 of human npro-IL-16, which includes the single HindIII site. Using this site, the amplified KpnI/HindIII fragment and a HindIII/NotI fragment, removed from the vector pcDNA3/pro-IL-16-V5, were fused in a ligation reaction with KpnI/NotI-digested pcDNA3-V5 to generate pcDNA/npro-IL-16-V5. The sequence of human npro-IL-16 reported in this paper was deposited in the GenBank TM data base (accession number AY324389)
RESULTS

Identification of Myosin Phosphatase Targeting Subunits as Pro-IL-16-interacting
Proteins-Yeast two-hybrid screens of a random-primed human spleen library and an oligo(dT)-primed PBL cDNA library were performed using the three PDZ domains (aa 324 -631) of human pro-IL-16 as bait (Fig. 1A) . Preliminary experiments showed no autoactivation of the EGY48 yeast strain by the lexA-PDZ1-3 fusion protein. Approximately 10 8 transformants of each library were analyzed. The screening of the spleen library resulted in 37 potentially positive clones. Restriction and sequence analysis revealed that 34 clones encoded the C-terminal region (aa 855-982 and 890 -982) of MYPT2 (Fig. 1B) . Among the 38 potential positives of the PBL library were 34 clones encoding two overlapping Cterminal sequences (aa 688 -782 and 753-782) of MBS85 (Fig.  1B) . The highly homologous C termini of MYPT2, MBS85, and the related protein MYPT1 (Fig. 1C) prompted us to determine the binding capacity of MYPT1 to the lexA-PDZ1-3 fusion bait. Introduction of an MYPT1 (aa 904 -1030) prey construct and the pEG202/PDZ1-3 bait vector into competent yeast resulted in rapid growth of blue colonies on selective media similar to that after transformation with the isolated MYPT2 and MBS85 (19 -21) . It has been shown that MYPT1 and MYPT2 are present in several variants or isoforms resulting from different splicing and use of an alternative promoter (22) . Not all of these variants encode the entire C-terminal regions shown to interact with the pro-IL-16 bait in the yeast two-hybrid experiments. In particular, the highly homologous terminal leucine zipper motif (Fig. 1C) is missing in MYPT2 variants containing exon 24, as shown by Arimura et al. (22) . Inclusion of this exon causes a frameshift resulting in an exchange of the very last 28 amino acids by 44 amino acids of exon 24. With respect to the high pro-IL-16 expression in stimulated PBL, we sought to confirm the presence of MYPT2, MBS85, and MYPT1 isoforms encoding the C-terminal leucine zipper by RT-PCR using isolated total mRNA and specific primers. For MYPT2 we extended the study by analyzing the expression of previously described variants (22) . As shown in Fig. 2 , major fragments of 365 and 1188 nucleotides were produced by PCR using primers encoding cDNA sequences of exon 20 and 25 or 13 and 25, respectively. These sizes were expected for transcripts lacking exon 24 (containing the terminal leucine zipper). Transcripts comprising exon 24 result in slightly larger fragments of 546 and 1369 nucleotides, respectively. Faint bands with these sizes are detectable, indicative of their presence at much lower levels compared with isoforms containing the terminal leucine zipper. No fragment could be amplified using a sense primer encoding a sequence downstream of the alternative promoter of intron 13, indicating that it is silent in PBL and no M21 (small subunit) variants are expressed.
Amplification of cDNA sequences with MBS85-and MYPT1-specific sense primers annealing upstream of the leucine zipper coding sequence and antisense primers binding downstream of the stop codon amplified only fragment sizes of 356 for MBS85 and 486 nucleotides for MYPT1, which are consistent with the pro-IL-16-interacting isoforms. Cloning and sequencing of all the major fragments confirmed the presence of the leucine zipper motifs. Thus, MYPT1, MYPT2, and MBS85 transcripts containing the C-terminal sequences shown to interact with pro-IL-16 in yeast two-hybrid experiments are all expressed in PBLs and seem to constitute the dominant isoforms.
The PDZ2 Domain of pro-IL-16 Interacts with MYPT1, MYPT2, and MBS85-To identify the PDZ domain that mediates binding to the myosin phosphatase targeting subunits we made LexA fusion constructs of PDZ2-3, PDZ2, PDZ3, and neural PDZ1-2 and performed yeast two-hybrid experiments using the phosphatase targeting subunits as prey. As summarized in Table I , all constructs containing the PDZ2 domain showed binding, whereas no interaction was detected when PDZ3 or the neural PDZ1-2 domains were transformed. The latter construct interacted with the cytoplasmic region of the NMDA receptor subunit NR2A, confirming the results of Kurschner and Yuzaki (11) . The hydrophobic GLGF loop is critically important for PDZ interactions, and mutations usually abrogate binding to the C terminus of the ligand (14) . Changing the GLGF sequence of the PDZ2 bait to KSGS completely abolished binding to all three targeting subunits, a result consistent with a typical mode of PDZ interaction. Interaction was also abrogated by deleting the binding pocket lining ␣-helix and the subsequent ␤-sheet of the domain. Removing residues upstream of PDZ2 up to amino acid 405 did not result
TABLE I Determination of the pro-IL-16 domain necessary for the interaction with MYPT2, MBS85, and MYPT1 using yeast two-hybrid assays
Numbers refer to amino acid residues of the respective proteins. PDZ2mut represents a construct carrying a change of the GLGF loop of PDZ2 to KSGS. NR2A represents a subunit of an NMDA receptor.
FIG. 2. Expression of MYPT2, MYPT1
, and MBS85 isoforms containing the leucine zipper motif in human blood cells. Total RNA from stimulated human PBLs was used in standard RT-PCR to confirm the expression of MYPT1, MYPT2, and MBS85 in these cells. Using the published gene structure of MYPT2 (22) we designed primers that allow discrimination between the major MYPT2 isoforms based on fragment size. The exon (Ex) or intron (In) corresponds to the cDNA sequences to which the primers bind is indicated. The sizes of the major MYPT2 fragments (365 bp on lane 1 and 1188 bp on lane 2) are in agreement with a lack of exon 24, leading to the expression of the C-terminal leucine zipper. No amplification of cDNA transcripts resulting from usage of an alternative promoter in intron 13 was possible (lane 3), indicating that small M21 MYPT2 isoforms are not expressed in PBLs. For the detection of MBS85 and MYPT1 a respective 356-and 486-bp fragment was amplified encompassing the C-terminal leucine zipper motif. All major fragments were sequenced to confirm the C-terminal isoforms. nt, nucleotides.
in any loss of binding activity, showing that these residues are not necessary for the interaction.
Analysis of the MYPT2 Sequence Sufficient for Binding to the PDZ2 of Pro-IL-16 in Yeast Two-hybrid Experiments-The
shortest sequence isolated in a yeast two-hybrid screen encoded the C-terminal 30 residues of MBS85. A corresponding construct containing the 30 C-terminal residues of MYPT2 also interacted with the PDZ2 bait, but a further truncation by 9 or more residues abolished the interaction (Table II) . Association was also abolished by C-terminal deletion of 2 or more residues of MYPT2 (Table II) and MBS85 (data not shown). Furthermore, deletion of the C-terminal lysine or the addition of an alanine to the MYPT2 sequence, which generates a canonical type I motif (SKA), did not abrogate the interaction. To further analyze the binding requirements we subsequently mutated the three C-terminal residues to alanine. The K982A mutant still interacted with the PDZ2 bait, whereas the S981A mutant did not. An ambiguous result was obtained with the L980A mutant, which yielded a mix of small white and blue yeast colonies indicative of a weak interaction. Based on these results, we conclude that the C-terminal 30 amino acids containing the leucine zipper are required for the interaction and that a critical role is played by the serine at the Ϫ1 position. This indicates a novel mode for a PDZ domain interaction engaging C-terminal residues of the ligand.
In Vitro Binding Assays-The interaction of MYPT2 with the second PDZ domain of pro-IL-16 demonstrated in the yeast two-hybrid experiments was reproduced by in vitro pull-down assays and plasmon resonance measurements. His 10 -tagged recombinant PDZ2 and PDZ3 domain proteins and two GST fusion proteins of MYPT2 were produced in bacteria. In addition to a GST-MYPT2-(855-982) containing the entire C-terminal 128 residues of MYPT2, we made a deletion mutant, GST-MYPT2-(855-978), lacking the C-terminal KLSK sequence. As shown in Fig. 3A , only the His 10 -PDZ2 protein associated with GST-MYPT2-(855-982) and no association with GST-MYPT2-(855-978) occurred. In agreement with the two-hybrid results, no binding of the His 10 -PDZ3 to GST-MYPT2-(855-982) proteins was evident. To directly observe the binding of His 10 -PDZ2 protein to GST-MYPT2-(855-982) and to assess the binding parameter, we immobilized similar amounts of GST-MYPT2-(855-982) and GST-MYPT2-(855-978) on BIAcore chips and performed surface plasmon resonance measurements by applying different concentrations of His 10 -PDZ2. Significant binding of His 10 -PDZ2 to GST-MYPT2-(855-982) could be seen in the nanomolar range (Fig. 3B) . The binding was specific, since no association with GST-MYPT2-(855-978) was detected. Unfortunately, a precise estimation of the binding parameters via curve-fitting using the assumed one-to-one binding model was not possible, probably due to some degree of unspecific aggregation of the soluble ligand.
Coimmunoprecipitation of Pro-IL-16 and Myosin Targeting Subunits from Transfected HEK 293T Cells-To test whether pro-IL-16 associates with MYPT2, MYPT1, and MBS85 in vivo,
we transiently expressed tagged versions of these proteins (pro-IL-16-V5, Myc-MYPT2, Myc-MYPT1, and FLAG-MBS85) in HEK 293T cells and performed coimmunoprecipitation experiments. 48 h after transfection cells were solubilized with Triton-X buffer, and cleared lysates were subjected to immunoprecipitation, resolved by SDS-PAGE, and immunoblotted. As shown in Fig. 4A , a Myc-tag specific antibody, but not an isotype control antibody, precipitated Myc-MYPT2 with bound pro-IL-16-V5. No pro-IL-16-V5 was detectable by the anti-Myc antibody if Myc-MYPT2 was not expressed. In reverse experiments, Myc-MYPT2 was coimmunoprecipitated with pro-IL-16-V5 using a V5-tag specific antibody, but was not detectable using an isotype control IgG. No protein equivalent in size to Myc-MYPT2 was visible in anti-V5 precipitates if Myc-MYPT2 was not expressed. Fig. 4B shows the results of similar experiments performed with FLAG-MBS85. Only the FLAG-tag specific antibody, but not the IgG control, coimmunoprecipitated pro-IL-16-V5. The anti-V5 antibody in the reverse experiment coimmunoprecipitated FLAG-MBS85. Similar experiments were done with Myc-MYPT1 and pro-IL-16-V5 expressing HEK 293T cells. As with Myc-MYPT2 and FLAG-MBS85, we found that Myc-MYPT1 also forms a complex with pro-IL-16-V5 in transiently transfected cells (data not shown).
To confirm the necessity of the C-terminal KLSK sequence of MYPT2 for the interaction with the PDZ2 domain of pro-IL-16, we expressed an Myc-tagged C-terminal segment of MYPT2 with and without this sequence. In contrast to the protein containing the wild type C terminus, no interaction was detected with the mutant lacking the C-terminal four amino acids (Fig. 4C) . Mutating the pro-IL-16-V5 PDZ2 GLGF-loop to KSGS almost completely abolished the interaction. With longer exposure times, however, a slight band could be detected, particularly in precipitations using the anti-V5 antibody (Fig. 4C) , indicating that a weak interaction or an indirect association of this mutant with the targeting subunit remains.
Coimmunoprecipitation of Endogenous Pro-IL-16 and MYPT1 from PBLs-The availability of pro-IL-16-and MYPT1-specific antibodies allowed the direct association of these proteins in activated human PBL to be tested. Immunoprecipitation from lysates using a human IL-16-specific polyclonal goat IgG, which recognizes epitopes outside of PDZ2, brought down MYPT1 (Fig. 5) . For the detection of MYPT1 and for the reverse experiments, a MYPT1-specific monoclonal antibody raised against a region outside of the leucine zipper was purchased from BD Biosciences. Using this antibody it was possible to coimmunoprecipitate pro-IL-16, further confirming the interaction of these proteins in PBLs.
Neuronal Pro-IL-16 Forms a Coprecipitable Complex with MYPT2-MYPT1, MYPT2, and MBS85 are all expressed in the brain. Their binding to PDZ2 of npro-IL-16 expressed in neurons might be critical for its function. To date, only the mouse sequence of this isoform has been published (11) . By using a 5Ј-rapid amplification of cDNA ends approach and cerebellum cDNA we cloned and sequenced the 141-kDa human npro-IL-16. At the amino acid level the proteins are 80% identical, with the highest homologies occurring in the PDZ domains (Fig. 6A) . The coimmunoprecipitations shown in Fig. 6B provide strong evidence that in addition to pro-IL-16, the neural isoform also interacts with myosin targeting subunits, as demonstrated for MYPT2. 
Colocalization of Pro-IL-16 and Myosin Phosphatase Targeting Subunits at F-actin and Myosin Filaments in Cotransfected
COS-7 Cells-We next examined a putative subcellular colocalization of pro-IL-16-V5 with Myc-tagged MYPT2, MYPT1, and FLAK-MBS85 in cotransfected COS-7 cells by laser scanning confocal microscopy. In agreement with earlier publications (22) we observed a perinuclear accumulation of pro-IL-16 in most cells using the anti-V5 (Fig. 7) or the 14.1 antibody (data not shown), which recognize an epitope in the C-terminal region of the protein. In addition, pro-IL-16-V5 immunofluorescence was also associated with submembranous sites and with cytoskeletal filaments, including stress fibers (Fig. 7A) . Double staining of pro-IL-16 with antibodies and F-actin with FITCphalloidin confirmed the identity of the fibers as F-actin. As expected, pro-IL-16 also showed a largely overlapping distribution with myosin in the perinuclear region, at stress fibers, and in the cell periphery (Fig. 7B) . A striking colocalization of pro-IL-16 with MYPT2, MYPT1, and to a lesser extent with MBS85 was evident at these actomyosin filaments. MBS85 was predominantly found in the perinuclear region of the cell (Fig. 7C ).
DISCUSSION
Our earlier work revealed the presence of a 67-kDa precursor of the cytokine IL-16 in PBLs (10). Pro-IL-16 contains three PDZ domains, characteristic protein interaction modules present in a number of intracellular scaffold proteins. These proteins typically target membrane receptors, ion channels, adhesion molecules, and other ligands to supramolecular signaling complexes and anchor them to the cytoskeleton (17) . The vast majority of PDZ domains bind to the C-terminal residues of the interacting protein, but association with internal sequences, dimerization of PDZ domains, and binding to other interaction modules including LIM domains, ankyrin repeats, and spectrin repeats have been reported (15, (23) (24) (25) .
In addition to the 67-kDa pro-IL-16 in lymphatic tissues, a 141-kDa isoform was found to be expressed in some neurons of the cerebellum and hippocampus (11) . The neural precursor contains two additional N-terminal PDZ modules that interact with several ion channel subunits, all possessing the C-terminal consensus sequence XSX(V/I/L). No binding of these subunits to the two C-terminal PDZ domains (PDZ2 and PDZ3), which are present in both precursor isoforms, was detected. No cellular ligands have so far been found for PDZ1 (which has the lowest homology with classical PDZ domains) or for PDZ2 and PDZ3. The latter domain is a major part of the C-terminal 121-amino acid fragment that constitutes the released cytokine (10) . This domain is unusual in several ways. It is the only PDZ domain so far found in a secreted protein and contains a very narrow binding pocket that is partially occluded by a conserved tryptophan side chain. None of the class I peptide ligands tested by Mü hlhahn et al. were found to interact with it and it is neither directly involved in binding of the cytokine to the CD4 receptor (26) nor seems to functions as a dimerization unit, based on a lack of interaction of PDZ3 bait and prey fusion proteins in our yeast two-hybrid experiments.
2 Nevertheless, it is conceivable that specific ligands for this domain exist that may interact in an unconventional manner possibly resembling the complex of PDZ7 of GRIP1 (which also has a narrow or closed binding pocket) with the Ras guanine nucleotide exchange factor GRASP1 (27) .
While searching for ligands of the three PDZ domains present in pro-IL-16 we found three myosin phosphatase targeting subunits, MYPT2, MBS85, and MYPT1, using a yeast twohybrid approach. The pro-IL-16-interacting proteins are splice variants containing a highly homologous C-terminal amino acid sequence encoding a short leucine zipper motif. The expression of these isoforms in PBLs was confirmed by RT-PCR. In vivo interaction was verified by coimmunoprecipitation experiments from transfected HEK 293T cells, and a complex of native, endogenous pro-IL-16 and MYPT1 was detected in activated human PBL. The interactions are mediated by the second PDZ domain of pro-IL-16 as no binding to other PDZ domains of the IL-16 precursors was detected. PDZ domains have a similar architecture and binding mode, but the rules underlying the specificity of the ligand recognition are only partially understood (28) . In the common interaction mode, the ligand fits into a pocket formed by ␤-strands, a conserved GLGF loop, and an ␣-helix (17) . We found that mutation of the hydrophobic GLGF sequence of the pro-IL-16 PDZ2 motif to KSGS completely abolished the interaction in yeast two-hybrid experiments and dramatically reduced the association of MYPT2 with pro-IL-16 in transfected cells to background levels. Further support for an involvement of the PDZ2 binding pocket comes from a deletion mutant lacking the ␣-helix and the subsequent ␤-strand. No interaction with MYPT2 could be detected using this construct as bait. As demonstrated with MYPT2, the 30 C-terminal residues comprising the zipper motif were necessary and sufficient for binding. In agreement with the vast majority of PDZ domain interactions, a deletion of the terminal four residues (KLSK) of all three isolated phosphatase targeting subunits completely prevented the association in yeast two-hybrid experiments as well as in coimmunoprecipitation assays. Moreover, as demonstrated with MYPT2, the same result was obtained by deleting only the last two residues, which does not change any of the zipper leucines. The C-terminal KLSK sequence of the interacting targeting subunits does not resemble any known PDZ binding motif (15, 28) . The most critical residue is the serine at the Ϫ1 position. Its mutation to alanine completely prevented binding, whereas the addition of an alanine, which creates a type I motif, and deletion or mutation of the terminal lysine to alanine, still allowed interaction. Terminal lysine or serine residues in PDZ motifs are not without precedence. The PDZ binding motif (EDAK) of the metabotropic glutamate receptor 6 (mGluR6), for example, interacts with PDZ domains of GRIP and syntenin, and PICK1 binds to mGluR6, which contains a C-terminal GSTS sequence (29) . The diversity of PDZ motifs is rapidly increasing with the identification of new interacting proteins and specificity determinants. Further work will be needed to explore the exact binding mode of the growing number of PDZ interactions.
The physiologic functions of myosin phosphatase targeting subunits has been mainly investigated in muscle cells where the associated catalytic phosphatase subunit (PP1c) controls the contractile activity (30) . Information concerning its role in non-muscle cells and tissues including the brain, with a demonstrated high expression level, is very limited. The phosphatase acts primarily on the regulatory myosin light chain 2, but substrates other than myosin chains may exist (30) . In addition to its function in targeting the catalytic subunit, the myosin binding subunits are able to form dimers and regulate enzyme activity by integrating signals of several signaling transduction pathways (31) (32) (33) (34) (35) (36) (37) (38) . Of special interest is the interaction of MYPT1 with cGMP-dependent protein kinase 1␣, which binds to the leucine zipper and phosphorylates serines in this region (37, 39) . The observation that L-type calcium channels bind to npro-IL-16 and are modulated by cGMP-dependent protein kinase 1␣ (40, 41) imply that a complex of npro-IL-16, L-type calcium channel, and MYPT1 could be formed that is controlled by this kinase. Further experiments will show whether cGMPdependent protein kinase 1␣ regulates binding of the IL-16 precursor proteins to MYPT1 by direct competition or by phosphorylation of the serine at the Ϫ1 and/or Ϫ4 position. Other critical factors that adjust myosin phosphatase activity are RhoA, which binds near the leucine zipper region, and the phosphorylation by Rho kinase after activation of Rho GTPases (31, 42) . These proteins are important regulatory molecules that link surface receptors to the organization of a contractile actin-myosin network. Rho family GTPases also control the formation of thick actin-myosin filaments known as stress fibers (43) . The association of pro-IL-16 with myosin phosphatase targeting subunits and actomyosin structures as demonstrated by colocalization in transfected COS-7 cells indicates a potential role for the IL-16 precursor in surface receptor-directed reorganization of the cytoskeleton leading to changes in cell morphology and/or cell motility. In this context a functional link to the chemotactic activity of the cytokine would exist. Alternatively, as has been shown with MBS85, treatment with lysophosphatidic acid and phorbol esters leads to a rapid translocation of the protein to the peripheral membrane (19) , suggesting an involvement in activation-induced cortical rearrangements or targeting of cytoplasmic or recycling proteins to the membrane. Several lines of evidence indicate that cellular motor proteins, including myosins, are key players in the trafficking of receptors and ion channels to the cellular membrane as well as in the opposite direction during endocytosis and protein sorting events (44 -46) . It has been shown in this context that a PDZ-mediated NMDA-postsynaptic density 95 com- plex is linked to myosin V and dynein by the guanylate kinase domain-associated protein (47) . Moreover, the activity of NMDA receptors is regulated by F-actin and myosin light chain kinase, indicating a regulatory function for the myosin phosphatase as well (48) . A complex of myosin phosphatase targeting subunits, npro-IL-16 and ion channels, raises the possibility that the interactions play a role in the processes of ion channel trafficking or positioning in the cortical cytoskeleton at the plasma membrane mentioned above. However, so far no interaction of the 67-kDa precursor expressed in lymphocytes with an integral membrane protein or proteins involved in endocytosis or the sorting machinery has been reported.
Of additional special interest is the impact of the reported associations on the poorly understood processing of both precursor variants and the release of the mature cytokine, which remains to be determined. The identification of more proteins that interact with the IL-16 precursors will certainly support or negate the potential implications discussed here and reveal the connection between the neuronal and the immune system in which the IL-16 precursors and the mature cytokine function.
